CCL21

Across TCGA pan-cancer cohorts, CCL21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCL21 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCL21 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CCL21 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where CCL21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.484	.038	30	view →
LUAD	OS	Quartile	III,IV	0.170	0.684	.012	13	view →
CCRCC	DFS	Median	III,IV	0.140	0.887	.038	6	view →
PDAC	OS	Median	II,III,IV	0.556	0.275	.011	4	view →
LSCC	DFS	Quartile	II,III,IV	0.355	0.749	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCL21–HNSC (OS)

Open the HNSC breakdown →